Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

Core Insights - Coherus Oncology is focused on enhancing the lives of cancer patients and aims to deliver significant improvements in survival rates [4] - The company's growth strategy consists of three distinct components, including existing and upcoming drugs [4] Company Overview - Coherus Oncology is dedicated to developing innovative therapies for cancer treatment [4] - The company is led by a team of experienced executives, including the CEO Dennis Lanfear and Chief Development Officer Theresa Lavallee [2][3] Pipeline and Strategy - The company is advancing its pipeline, which includes LOQTORZI, a next-generation PD-1 therapy [5] - Coherus believes it has the right strategy to drive growth and achieve its objectives in the oncology market [4]